Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251553 | 1.00 | CNR1 (0.46) | CNR1ALDH1A1CNR2LPAR1LPAR2 | |
| SCHEMBL170865 | 0.95 | ALDH1A1 (0.54) | CNR1ALDH1A1CNR2 | |
| SCHEMBL945677 | 0.95 | ALDH1A1 (0.54) | CNR1ALDH1A1CNR2 | |
| SCHEMBL251629 | 0.90 | SPHK1 (0.43) | LPAR1LPAR2LPAR3 | |
| SCHEMBL5561906 | 0.90 | SPHK1 (0.43) | LPAR1LPAR2LPAR3 | |
| SCHEMBL27320 | 0.86 | ALDH1A1 (0.43) | CNR1ALDH1A1CNR2LPAR1LPAR2 | |
| SCHEMBL1921025 | 0.82 | ALDH1A1 (0.56) | CNR1ALDH1A1CNR2 | |
| Trimethylammonium SCHEMBL129171 | 0.79 | CNR1 (0.45) | CNR1ALDH1A1CNR2LPAR1LPAR2 | |
| SCHEMBL30442607 | 0.79 | SPHK1 (0.44) | CNR1ALDH1A1CNR2LPAR1LPAR2 | |
| SCHEMBL14834011 | 0.79 | CNR1 (0.47) | CNR1ALDH1A1CNR2LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1656 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4321504-B1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | XIAMEN SINOPEG BIOTECH CO LTD (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4652281-A2 | GENE EDITING FOR SURGERY-RELATED FIBROSIS TREATMENT | Orthobio Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | claimed |
| US-12414918-B2 | Pharmaceutical composition of lipid nanoparticle for delivering nucleic acid drug containing trehalose derivative and novel structure-maintaining lipid compound | SML BIOPHARM CO., LTD. (KR) | 2025-09-16 | — | — | US | claimed |
| US-20250263681-A1 | LIPID NANOPARTICLES FOR GENE EDITING SYSTEMS | ORTHOBIO THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | claimed |
| US-20250228969-A1 | GENE EDITING TO IMPROVE JOINT FUNCTION | ORTHOBIO THERAPEUTICS, INC. | 2025-07-17 | — | — | US | claimed |
| WO-2025133684-A1 | LIPOSOMAL NANOPARTICLES FOR CRISPR/CAS9 DELIVERY | VILNIUS UNIVERSITY (LT) | 2025-06-26 | — | — | WO | claimed |
| US-20250161494-A1 | TRANSMEMBRANE RECEPTOR GENE EDITING | ORTHOBIO THERAPEUTICS INC (US) | 2025-05-22 | — | — | US | claimed |
| WO-2017201348-A1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201349-A1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201347-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201346-A1 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201333-A1 | POLYNUCLEOTIDES ENCODING LIPOPROTEIN LIPASE FOR THE TREATMENT OF HYPERLIPIDEMIA | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201328-A1 | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| US-20170273907-A1 | STABLE FORMULATIONS OF LIPIDS AND LIPOSOMES | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2017-09-28 | — | — | US | claimed |
| WO-2017127750-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2017-07-27 | — | — | WO | claimed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | claimed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161494-A1 | TRANSMEMBRANE RECEPTOR GENE EDITING | LDLR, NGFR, APLNR | CNR1 289/4885ALDH1A1 1454/4885CNR2 358/4885 |
| US-12414918-B2 | Pharmaceutical composition of lipid nanoparticle for delivering nucleic acid drug containing trehalose derivative and novel structure-maintaining lipid compound | RNMT, RPN2, DDOST | CNR1 4641/4885ALDH1A1 4370/4885CNR2 4830/4885 |
| US-20250228969-A1 | GENE EDITING TO IMPROVE JOINT FUNCTION | ROS1, SYVN1, ATF4 | CNR1 3933/4885ALDH1A1 2454/4885CNR2 3940/4885 |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | CNR1 709/4885ALDH1A1 2430/4885CNR2 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.